XSPRAY Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 32.05 |
| 52 Week High | SEK 91.70 |
| 52 Week Low | SEK 23.00 |
| Beta | 0.64 |
| 1 Month Change | -5.74% |
| 3 Month Change | 6.30% |
| 1 Year Change | -56.92% |
| 3 Year Change | -44.36% |
| 5 Year Change | -71.64% |
| Change since IPO | 2.07% |
Recent News & Updates
Recent updates
Is Xspray Pharma (STO:XSPRAY) Weighed On By Its Debt Load?
Apr 03
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully
Feb 25We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
May 11We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth
Feb 01We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Oct 26We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate
Jun 20We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely
Mar 19Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?
Feb 12Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation
Dec 04
Shareholder Returns
| XSPRAY | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.1% | 1.0% | -0.9% |
| 1Y | -56.9% | -7.5% | -5.0% |
Return vs Industry: XSPRAY underperformed the Swedish Biotechs industry which returned -9.4% over the past year.
Return vs Market: XSPRAY underperformed the Swedish Market which returned -4.6% over the past year.
Price Volatility
| XSPRAY volatility | |
|---|---|
| XSPRAY Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 4.3% |
Stable Share Price: XSPRAY has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: XSPRAY's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 26 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa S.r.l for production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
| XSPRAY fundamental statistics | |
|---|---|
| Market cap | SEK 1.19b |
| Earnings (TTM) | -SEK 260.07m |
| Revenue (TTM) | n/a |
Is XSPRAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XSPRAY income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 260.07m |
| Earnings | -SEK 260.07m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | -7.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.5% |
How did XSPRAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 14:57 |
| End of Day Share Price | 2025/06/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dan Akschuti | Pareto Securities |
| Filip Einarsson | Redeye |